Retrospective analysis shows high complete response and manageable adverse events in patients with myeloproliferative neoplasms, indicating effective treatment with Pegylated Interferon.
Key Points
Patients experienced a 99.12% overall response rate at 12 months, with substantial symptom improvement noted in this analysis.
The study involved 210 patients with myeloproliferative neoplasms, reporting 97.6% molecular response rate among evaluable cases.
Retrospective study assessed treatment outcomes and adverse events across 10 centers, focusing on real-world efficacy and patient safety.
Significant findings support the use of Pegylated Interferon in managing myeloproliferative neoplasms, though further studies are warranted for broader application.